Engineering CAR T Cells to Resist Tumor Immune Suppression - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • March 9, 2026

  • 2 min

Share

Original Source(s)

Engineering CAR T Cells to Resist Tumor Immune Suppression

  • March 9, 2026

Related Content

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma